Project Grant R01NS148580
Award Date 9/1/26
Completion Date 7/31/31
Dollars Obligated $600K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Sarasota, FL 34243, USA
Similar Awards
- The National Institute on Aging (NIA) awarded a $341,000 Project Grant (CFDA 93.866 - Aging Research) to The Roskamp Institute, Inc. in Sarasota, FL. The grant will support research to investigate the impact of the APOE4 genotype, a major genetic risk factor for Alzheimer's disease, on brain bioenergetics. The goal is to examine how APOE4-mediated disturbances in fatty acid metabolism and energy substrate availability within the cerebrovascular system and astrocytes contribute to neuronal energy...
- The National Institute on Aging awarded Icahn School of Medicine at Mount Sinai $2.944 million on June 1, 2026, under the Aging Research program (CFDA 93.866) to investigate systemic roles of apolipoprotein E (APOE) genotypes in central nervous system health and Alzheimer's disease pathology. The research uses plasma transfer and parabiosis models to examine how blood-borne factors and APOE genotype-specific mediators influence blood-central nervous system neuroimmune communication. The...
- This Project Grant award, funded by the National Institute on Aging's Aging Research program (CFDA 93.866), supports research to investigate how the APOE genotype affects the production and composition of mitovesicles, a type of extracellular vesicle derived from mitochondria, in the brain. The $2,499,343 award, with a performance period from Sep 1, 2024 to Aug 31, 2027, will be led by the Research Foundation for Mental Hygiene, Inc. (RFMH) at the Nathan S. Kline Institute. The project aims to...
- The National Institute on Aging awarded Rensselaer Polytechnic Institute $698,712 on September 1, 2026, under the Aging Research program (CFDA 93.866) to investigate apolipoprotein E and reelin interactions in Alzheimer's disease pathology. The research tests the hypothesis that APOE E4 competes with reelin for receptor and heparan sulfate binding, thereby reducing protective reelin signaling and increasing Alzheimer's disease risk. Work includes mechanistic studies using split luciferase assays...
- The National Institute on Aging awarded $1.602 million to J. David Gladstone Institutes on February 15, 2026, under the Aging Research program (CFDA 93.866) to investigate how the APOE4 genetic allele disrupts brain energy metabolism in Alzheimer's disease. Work is performed in San Francisco, California through January 31, 2031. The award funds research using live imaging and mass spectrometry to measure metabolic fluxes in mouse models and magnetic resonance spectroscopic imaging to assess...
- The National Institute on Aging awarded Brown University $636,372 on June 15, 2026, under the Aging Research program (CFDA 93.866) to support multimodal optical imaging and AI analytics investigating APOE4 etiology and therapeutic targets in late-onset Alzheimer's disease. The research applies label-free optical coherence tomography angiography (OCTA) and two-photon calcium imaging to map vascular topology and flow heterogeneity in APOE4 mice from 12 to 48 weeks of age while tracking...
- The National Institute on Aging awarded the Fatty Acid Research Institute $412,500 on September 1, 2026, under the Aging Research program (CFDA 93.866) to establish interaction polygenic risk scores for blood omega-3 fatty acids and genetic variants as predictors of incident all-cause dementia and Alzheimer's disease. The research identifies genetic variants that interact with blood docosahexaenoic acid (DHA) levels as risk factors for Alzheimer's disease and related dementias, with the goal...
- The National Institute of Neurological Disorders and Stroke, part of the Department of Health and Human Services National Institutes of Health, awarded Albany Medical College $1.951689 million on June 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The award funds investigation of inflammation-resolution pathways to address vascular contributions to cognitive impairment and dementia (VCID) in the context of atherosclerosis....
- The National Institute on Aging awarded a $2,250,745 Project Grant (CFDA 93.866 - Aging Research) to Mayo Clinic Jacksonville, doing business as Scott Lynch MD, to conduct research on the role of apolipoprotein E (APOE) in meningeal lymphatic function and its impact on Alzheimer's disease pathophysiology. The research aims to uncover the effects of APOE4 expression on meningeal lymphatic drainage and immune cell interactions, and how this may contribute to neuroinflammation and amyloid-β...
- The National Institute on Aging awarded the University of Massachusetts Medical School $419,946 on September 1, 2026, under the Aging Research program (CFDA 93.866) for research into RNA interference-mediated modulation of apolipoprotein E, innate immune response, and tau pathology as a disease-modifying treatment for Alzheimer's disease. The funded research develops and tests small interfering RNA scaffolds that simultaneously target multiple genes implicated in Alzheimer's disease progression....